Advertisement

Gastro-News

, Volume 5, Issue 3, pp 41–46 | Cite as

Epidemiologie, Pathogenese und moderne therapeutische Konzepte

Resektion bleibt beste Therapieoption bei Cholangiokarzinomen

fortbildung

Die Entität „Cholangiokarzinom“ ist eine heterogene Gruppe von Tumoren, die in der Diagnostik und Therapie viele Disziplinen zusammenführt. Dabei kommt der primären Ausbreitungsdiagnostik und der Entscheidung, ob die perihilären Tumoren operabel sind, eine zentrale Bedeutung zu.

Literatur

  1. 1.
    Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 1992; 215:31.CrossRefGoogle Scholar
  2. 2.
    DeOliveira ML, Schulick RD, Nimura Y, Rosen C, Neuhaus P, Clavien PA New staging system and a registry for perihilar cholangicarcinoma Heatology;2011;531363–1371)Google Scholar
  3. 3.
    DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245:755.CrossRefGoogle Scholar
  4. 4.
    Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33:1353.CrossRefGoogle Scholar
  5. 5.
    Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004; 40:472.CrossRefGoogle Scholar
  6. 6.
    Jepsen P, Vilstrup H, Tarone RE, et al. Incidence rates of intra- and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002. J Natl Cancer Inst 2007; 99:895.CrossRefGoogle Scholar
  7. 7.
    West J, Wood H, Logan RF, et al. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer 2006; 94:1751.CrossRefGoogle Scholar
  8. 8.
    Rajagopalan V, Daines WP, Grossbard ML, Kozuch P. Gallbladder and biliary tract carcinoma: A comprehensive update, Part 1. Oncology (Williston Park) 2004; 18:889.Google Scholar
  9. 9.
    Khan SA, Taylor-Robinson SD, Toledano MB, et al. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37:806.CrossRefGoogle Scholar
  10. 10.
    Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2:10.CrossRefGoogle Scholar
  11. 11.
    Welzel TM, McGlynn KA, Hsing AW, et al. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2006; 98:873.CrossRefGoogle Scholar
  12. 12.
    Khan SA, Emadossadaty S, Ladep NG, et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol 2012; 56:848.CrossRefGoogle Scholar
  13. 13.
    Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005; 128:620.CrossRefGoogle Scholar
  14. 14.
    Khan SA Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg SM, Tait P, Taylor Robisnon SD, Thillainayagam AV, Thomas HC, Wasan H Guidelines for the diagnosis and treatment of cholangicarcinoma: an update Br Soc Gastroenterol 2012; 6:1657–1669Google Scholar
  15. 15.
    Maccioni F, Martinelli M, Al Ansari N, Kargamanova A, De Marco V, Zippi M, Marini M: Magnetic resonance cholangiography: past, present and future:a review Eur Rev Med Pharmacol Sci 2010;14: 721–725PubMedGoogle Scholar
  16. 16.
    Heimbach JK, Sanchez W, Rosen CB Gores GJ. Trans-peritoneal fine needle aspiration biopsy of hilar cholangicarcinoma is associated with disease dissemination HPB 2012;13: 356–360Google Scholar
  17. 17.
    Trikudanathan G Navaneethan U, Njei B, Vargo JJ, Parsi MA: Diagnostic yield of bile ducht brushings for cholangiocarcinoma in primary sclerosing cholangitis; a systematic review and metaanalysis Gastrointest Endosc 2014; 79:783–789Google Scholar
  18. 18.
    Dudley JC et al. Next generation sequencing and fluorescence in situ hybridization hab’ve comparable performance characteritics in the analysis of pancreaticobilary brushings for malignancy J Mol Diagn 2016;18:124Google Scholar
  19. 19.
    Li L et al. Human bile contains micro RNA-laden extracellular vesicels that can be used for Cholangiocarcinoma diagnosis. Hepatology 2014;60:896–907CrossRefGoogle Scholar
  20. 20.
    Patel AH, Harnois DM, Klee GG, La Russo NF, Gores GJ: Then utility of CA 19-9 in the diagnosis of cholangiocarcinoma without primary sclerosin cholangitis Am J Gastroenterol 2000;95:204–207CrossRefGoogle Scholar
  21. 21.
    Dodson RM, Weiss MJ, Cosgrove D, et al.: Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg 217(4): 736–750.e4, 2013.CrossRefGoogle Scholar
  22. 22.
    Guro H, Kim JW, Choi Y, Cho JY, Yoon YS, Han HS Multidisciplinary management of intrahepatic cholangiocarcinoma: Current approaches. Surg Oncol. 2017 Jun;26(2):146–152CrossRefGoogle Scholar
  23. 23.
    Washburn WK, Lewis WD, Jenkins RL: Aggressive surgical resection for cholangiocarcinoma. Arch Surg 130(3): 270–6, 1995.CrossRefGoogle Scholar
  24. 24.
    Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143:88.CrossRefGoogle Scholar
  25. 25.
    Loveday BPT, Knox JJ3, Dawson LA, Metser U, Brade A4, Horgan AM, Gallinger S, Greig PD, Moulton CA Neoadjuvant hyperfractionated chemoradiation and liver transplantation for unresectable perihilar cholangiocarcinoma in Canada. J Surg Oncol. 2018 Feb;117(2):213–219CrossRefGoogle Scholar
  26. 26.
    Ortner ME, Caca K, Berr F, Liebetruth J, Mansmann U, Huster D, Voderholzer W, Schachschal G, Mössner J, Lochs H. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study Gastroenterology. 2003 Nov;125(5):1355–63Google Scholar
  27. 27.
    Wang AY, Yachimski PS Endoscopic management of pancreatobiliary neoplasms. Gastroenterology. 2018 Feb 16. [Epub ahead of print]Google Scholar
  28. 28.
    Park DH, Lee SS, Park SE, Lee JL, Choi JH, Choi HJ, Jang JW, Kim HJ, Eum JB, Seo DW, Lee SK, Kim MH, Lee JB. Eur J Cancer 2014;50:1259–1268CrossRefGoogle Scholar
  29. 29.
    Schmidt A, Bloechinger M, Weber A, Siveke J, von Delius S, Prinz C, Schmitt W, Schmid RM, Neu B Short-term effects and adverse events of endoscopically applied radiofrequency ablation appear to be comparable with photodynamic therapy in hilar cholangiocarcinoma. UEG J 2016 (4):570–9Google Scholar
  30. 30.
    Valle J, Wasan H, Palmer DH, et al.: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14): 1273–81CrossRefGoogle Scholar
  31. 31.
    Pimrose JN et al. Adjuvant Capecitabine for bilary tract cancer:The BILCAP randomized Study (Abstract) J Clin Oncol 2017; 35(Suppl 15) 4006Google Scholar
  32. 32.
    Edeline KJ et al. Gemox vs. surveillance following surgery of localized bilary tract cancer J Clin Oncol 2017;35:225Google Scholar
  33. 33.
    Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, Ohtsuka M, Kaneoka Y, Yamamoto M, Ambo Y, Shimizu Y, Ozawa F, Fukutomi A, Ando M, Nimura Y, Nagino M; Bile Duct cancer Adjuvant Trial (BCAT) Study Group. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer Br J Surg. 2018;105(3):192–202.PubMedGoogle Scholar
  34. 34.
    Barney BM, Olivier KR, Miller RC, et al.: Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol 7: 67, 2012., 2010.Google Scholar
  35. 35.
    Rizvi S, Khan SA, Hallemeier C, Kelley RK, Gores GJ Cholangiocarcinoma-evolving concepts and thereutic strategies. Clinical oncology 2017: 1 — 17. Published online).Google Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Ärztlicher Direktor und Chefarzt der Medizinischen Klinik 2 Diakonissenkrankenhaus MannheimMannheimDeutschland

Personalised recommendations